Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells (Q37291635)

From Wikidata

Jump to navigation Jump to search

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

scientific article published on 12 May 2009

Language	Label	Description	Also known as
English	Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells	scientific article published on 12 May 2009

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells (English)

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

multiple myeloma

1 reference

based on heuristic

inferred from title

Paul G. Richardson

9

object named as

Paul G Richardson

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Kenneth C. Anderson

11

object named as

Kenneth C Anderson

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

2

object named as

Hiroshi Ikeda

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Nikhil V Munshi

8

object named as

Nikhil C Munshi

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

5

object named as

Noopur Raje

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Dharminder Chauhan

3

object named as

Dharminder Chauhan

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

1

object named as

Teru Hideshima

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

6

object named as

Klaus Podar

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Constantine S Mitsiades

7

object named as

Constantine Mitsiades

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Ruben Perez-Carrasco

10

object named as

Ruben D Carrasco

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

author name string

Yutaka Okawa

4

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

language of work or name

0 references

publication date

12 May 2009

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

114

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

5

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

1046-1052

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2721785

6 September 2017

Bortezomib-resistant nuclear factor-kappaB activity in multiple myeloma cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2721785

6 September 2017

A critical role of RICK/RIP2 polyubiquitination in Nod-induced NF-kappaB activation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2721785

6 September 2017

Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2721785

6 September 2017

Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2721785

6 September 2017

Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2721785

6 September 2017

Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2721785

6 September 2017

Ubiquitin-mediated activation of TAK1 and IKK.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2721785

6 September 2017

The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2721785

6 September 2017

PP2A regulates BCL-2 phosphorylation and proteasome-mediated degradation at the endoplasmic reticulum

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2721785

6 September 2017

NF-kappaB: linking inflammation and immunity to cancer development and progression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2721785

6 September 2017

A phase 2 study of bortezomib in relapsed, refractory myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2721785

6 September 2017

Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2721785

6 September 2017

Molecular sequelae of proteasome inhibition in human multiple myeloma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2721785

6 September 2017

Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2721785

6 September 2017

NF-kappa B as a therapeutic target in multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2721785

6 September 2017

The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2721785

6 September 2017

Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2721785

6 September 2017

Involvement of NF-kappaB in silica-induced cyclooxygenase II gene expression in rat alveolar macrophages

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2721785

6 September 2017

The NF-kappa B and I kappa B proteins: new discoveries and insights

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2721785

6 September 2017

Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2721785

14 September 2017

Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2721785

14 September 2017

Proteasome inhibitors induce death but activate NF-kappaB on endometrial carcinoma cell lines and primary culture explants

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2721785

14 September 2017

Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2721785

14 September 2017

A novel NF-kappaB pathway involving IKKbeta and p65/RelA Ser-536 phosphorylation results in p53 Inhibition in the absence of NF-kappaB transcriptional activity.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2721785

14 September 2017

A mechanistic insight into a proteasome-independent constitutive inhibitor kappaBalpha (IkappaBalpha) degradation and nuclear factor kappaB (NF-kappaB) activation pathway in WEHI-231 B-cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2721785

14 September 2017

Bortezomib inhibits human osteoclastogenesis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2721785

3 September 2018

A selective small molecule IkappaB Kinase beta inhibitor blocks nuclear factor kappaB-mediated inflammatory responses in human fibroblast-like synoviocytes, chondrocytes, and mast cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2721785

3 September 2018

Rapid TNFR1-dependent lymphocyte depletion in vivo with a selective chemical inhibitor of IKKbeta

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2721785

3 September 2018

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2721785

3 September 2018

Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2721785

3 September 2018

The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2721785

3 September 2018

BMS-345541 is a highly selective inhibitor of I kappa B kinase that binds at an allosteric site of the enzyme and blocks NF-kappa B-dependent transcription in mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2721785

3 September 2018

Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2721785

3 September 2018

Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2721785

3 September 2018

The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2721785

3 September 2018

CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-kappa B signaling

1 reference

https://pubmed.ncbi.nlm.nih.gov/19436050

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B

1 reference

https://pubmed.ncbi.nlm.nih.gov/19436050

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo

1 reference

https://pubmed.ncbi.nlm.nih.gov/19436050

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interference with nuclear factor kappa B and c-Jun NH2-terminal kinase signaling by TRAF6C small interfering RNA inhibits myeloma cell proliferation and enhances apoptosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/19436050

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1182/BLOOD-2009-01-199604

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37291635&oldid=2091260244"